Literature DB >> 26378646

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.

Christine Pocha1, Philippe Kolly1, Jean-Francois Dufour1.   

Abstract

Hepatocellular carcinoma (HCC) is a cancer with globally rising incidence. Growing evidence supports associations between metabolic syndrome and diabetes as well as obesity and HCC arising in patients with nonalcoholic fatty liver disease (NAFLD). This constitutes a problem of alarming magnitude given the rising epidemic of these conditions. The role of diabetes seems to be particularly important when associated with obesity or cirrhosis. Excess hepatic iron may be another potential risk factor for the development of NAFLD-associated HCC. In the context of NAFLD, HCC frequently develops in a not-yet cirrhotic liver. As there are no surveillance programs for these patients, diagnosis often occurs at a tumor stage beyond curative options. Clinical, tumor, and patient characteristics in NAFLD-associated HCC differ from other etiologies. Older age and cardiovascular comorbidities may limit treatment options further. The outcome in patients with NAFLD-associated early HCC is excellent and therefore aggressive treatment should be pursued in appropriate patients. Population-based prevention to reduce the culprit-NAFLD-early recognition through targeted surveillance programs in risk-stratified patients and effective treatment of HCC associated with NAFLD are urgently needed. In this review, the authors summarize the epidemiology, risk factors, features, and prevention of NAFLD-associated HCC. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26378646     DOI: 10.1055/s-0035-1562949

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

1.  Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.

Authors:  Sofia de Oliveira; Ruth A Houseright; Alyssa L Graves; Netta Golenberg; Benjamin G Korte; Veronika Miskolci; Anna Huttenlocher
Journal:  J Hepatol       Date:  2018-12-18       Impact factor: 25.083

2.  Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas.

Authors:  Mehmet Sayiner; Zobair M Younossi
Journal:  Hepat Oncol       Date:  2016-03-23

Review 3.  Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis.

Authors:  Jens U Marquardt; Marc Nguyen-Tat; Peter R Galle; Marcus A Wörns
Journal:  Visc Med       Date:  2016-04-08

Review 4.  Linking Race, Cancer Outcomes, and Tissue Repair.

Authors:  Jung S Byun; Samson Park; Ambar Caban; Alana Jones; Kevin Gardner
Journal:  Am J Pathol       Date:  2017-11-11       Impact factor: 4.307

Review 5.  Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Gastroenterology       Date:  2016-01-16       Impact factor: 22.682

Review 6.  Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies?

Authors:  Christine Pocha; Chencheng Xie
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-09

7.  Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.

Authors:  Tian Yang; Lun-Yang Hu; Zhen-Li Li; Kai Liu; Han Wu; Hao Xing; Wan Yee Lau; Timothy M Pawlik; Yong-Yi Zeng; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Jun Han; Chao Li; Ming-Da Wang; Meng-Chao Wu; Feng Shen
Journal:  J Gastrointest Surg       Date:  2019-01-07       Impact factor: 3.452

8.  Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit.

Authors:  Pao-Yuan Lin; Chih-Hung Chen; Christopher Glenn Wallace; Kuan-Hung Chen; Chia-Lo Chang; Hong-Hwa Chen; Pei-Hsun Sung; Kun-Chen Lin; Sheung-Fat Ko; Cheuk-Kwan Sun; Hsueh-Wen Chang; Pei-Lin Shao; Mel S Lee; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 9.  Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.

Authors:  Paul D Berk; Elizabeth C Verna
Journal:  Clin Liver Dis       Date:  2016-02-18       Impact factor: 6.126

Review 10.  Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2016-04-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.